To investigate the distribution of Human papillomavirus (HPV)-31 A, B and C variants as well as the common amino acid polymorphisms in Chinese women, all 14 HPV-31 positive cervical exfoliated cell specimens identified from a descriptive study including ~2700 women from Northern China were analyzed. HPV-31 positive specimens were identified by Mass Spectrometry and the fragments of partial Long Control Region, E6 and E7 were amplified and directly sequenced or cloned into vector and then sequenced to confirm the variant information. HPV-31 prevalence in Northern Chinese female population was 0.52%. Six different sequences represented all 14 isolates, and these isolates were subsequently classified into variant lineage A (9), B (0) and C (5) by phylogenetic analysis. Five common amino acid polymorphism sites (2 in E6 and 3 in E7) and a novel non-synonymous mutation were detected in the current study. Our investigation suggested that HPV-31 was much less detected in Chinese women population than that in western countries. A and C variants were commonly detected while B variants were rarely detected in this population.
References
[1]
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17–27. doi: 10.1016/j.virol.2004.03.033
[2]
de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM (2012) Susceptibility to cervical cancer: an overview. Gynecol Oncol 126: 304–311. doi: 10.1016/j.ygyno.2012.03.047
[3]
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527. doi: 10.1056/nejmoa021641
[4]
zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384: 260–265. doi: 10.1016/j.virol.2008.11.046
[5]
Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, et al. (2007) High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 120: 1763–1768. doi: 10.1002/ijc.22481
[6]
Bernard HU, Calleja-Macias IE, Dunn ST (2006) Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 118: 1071–1076. doi: 10.1002/ijc.21655
[7]
Chagas BS, Batista MV, Crovella S, Gurgel AP, Silva Neto Jda C, et al. (2013) Novel E6 and E7 oncogenes variants of human papillomavirus type 31 in Brazilian women with abnormal cervical cytology. Infect Genet Evol 16: 13–18. doi: 10.1016/j.meegid.2013.02.001
[8]
Ferenczi A, Gyongyosi E, Szalmas A, Hernadi Z, Toth Z, et al. (2013) Sequence variation of human papillomavirus type 31 long control region: phylogenetic and functional implications. J Med Virol 85: 852–859. doi: 10.1002/jmv.23542
[9]
Chagas BS, Batista MV, Guimaraes V, Balbino VQ, Crovella S, et al. (2011) New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil. Gynecol Oncol 123: 284–288. doi: 10.1016/j.ygyno.2011.07.008
[10]
Cento V, Rahmatalla N, Ciccozzi M, Perno CF, Ciotti M (2011) Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology. J Med Virol 83: 1752–1761. doi: 10.1002/jmv.22201
[11]
Raiol T, Wyant PS, de Amorim RM, Cerqueira DM, Milanezi N, et al. (2009) Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, -52, and -58 in central Brazil. J Med Virol 81: 685–692. doi: 10.1002/jmv.21432
[12]
Calleja-Macias IE, Kalantari M, Huh J, Ortiz-Lopez R, Rojas-Martinez A, et al. (2004) Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 319: 315–323. doi: 10.1016/j.virol.2003.11.009
[13]
Gagnon S, Hankins C, Tremblay C, Pourreaux K, Forest P, et al. (2005) Polymorphism of human papillomavirus type 31 isolates infecting the genital tract of HIV-seropositive and HIV-seronegative women at risk for HIV infection. J Med Virol 75: 213–221. doi: 10.1002/jmv.20259
[14]
Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, et al. (2011) Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. Plos One Volume 6: e20183. doi: 10.1371/journal.pone.0020183
[15]
Xi LF, Schiffman M, Koutsky LA, He Z, Winer RL, et al. (2013) Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage. Int J Cancer 132: 549–555. doi: 10.1002/ijc.27689
[16]
Xi LF, Schiffman M, Koutsky LA, Hulbert A, Lee SK, et al. (2012) Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2–3. Int J Cancer 131: 2300–2307. doi: 10.1002/ijc.27520
[17]
Liu F, Guo F, Zhou Y, He Z, Tian X, et al. (2012) The anyang esophageal cancer cohort study: study design, implementation of fieldwork, and use of computer-aided survey system. PLoS One 7: e31602. doi: 10.1371/journal.pone.0031602
[18]
Yi X, Li J, Yu S, Zhang A, Xu J, et al. (2011) A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part I. Anatomic Pathology 136: 913–919. doi: 10.1309/ajcpwtzdt0q7dovi
[19]
Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876–4882. doi: 10.1093/nar/25.24.4876
[20]
Page RD (1996) TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 12: 357–358. doi: 10.1093/bioinformatics/12.4.357
[21]
Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, et al. (1993) The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 67: 6413–6423.
[22]
Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, et al. (1995) Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 69: 7743–7753.
[23]
Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, et al. (2001) Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 93: 1325–1330. doi: 10.1093/jnci/93.17.1325
[24]
Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, et al. (2006) Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 98: 1045–1052. doi: 10.1093/jnci/djj297
[25]
Stoppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, et al. (1996) Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 70: 6987–6993.
[26]
Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, et al. (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1: 464–470. doi: 10.1038/nm0595-464
[27]
Bao YP, Li N, Smith JS, Qiao YL (2008) Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 18: 71–79. doi: 10.1111/j.1525-1438.2007.00959.x
[28]
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621–632. doi: 10.1002/ijc.22527
[29]
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202: 1789–1799. doi: 10.1086/657321
[30]
Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, et al. (1994) Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 152: 3904–3912.
[31]
Werness BA, Munger K, Howley PM (1991) Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression. Important Adv Oncol: 3–18.
[32]
Munger K, Scheffner M, Huibregtse JM, Howley PM (1992) Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 12: 197–217.
[33]
Crook T, Vousden KH (1994) Interaction of HPV E6 with p53 and associated proteins. Biochem Soc Trans 22: 52–55.
[34]
Farthing AJ, Vousden KH (1994) Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol 2: 170–174. doi: 10.1016/0966-842x(94)90667-x
[35]
Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, et al. (1990) The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 9: 153–160.
[36]
Foster SA, Demers GW, Etscheid BG, Galloway DA (1994) The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68: 5698–5705.
[37]
Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547–556. doi: 10.1016/0092-8674(91)90529-8
[38]
Dyson N, Guida P, Munger K, Harlow E (1992) Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 66: 6893–6902.
